Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IDXX IDEXX Laboratories	$645.68 +2.0%	$567.48	$356.14 ▼ $688.12	$51.62B	1.49	720,535 shs	146,668 shs
ISRG Intuitive Surgical	$475.71 +1.2%	$505.14	$425.00 ▼ $616.00	$170.40B	1.59	1.98 million shs	828,378 shs
NVST Envista	$21.52 +5.2%	$19.97	$14.22 ▼ $23.00	$3.58B	1	2.57 million shs	682,310 shs
ZTS Zoetis	$156.86 +0.8%	$154.00	$139.70 ▼ $200.33	$69.53B	0.88	3.09 million shs	969,126 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IDXX IDEXX Laboratories	-1.06%	-3.20%	+18.99%	+26.21%	+27.89%
ISRG Intuitive Surgical	-2.20%	-1.51%	-8.05%	-12.91%	-3.60%
NVST Envista	-1.30%	-1.98%	+1.95%	+22.12%	+13.46%
ZTS Zoetis	-0.77%	+1.52%	+2.84%	-4.56%	-14.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IDXX IDEXX Laboratories	4.3372 of 5 stars	2.4	4.0	0.0	3.7	4.1	2.5	1.3
ISRG Intuitive Surgical	4.8812 of 5 stars	4.3	3.0	0.0	4.0	3.6	2.5	1.9
NVST Envista	3.6881 of 5 stars	2.2	3.0	0.0	3.8	2.9	0.0	1.9
ZTS Zoetis	4.8905 of 5 stars	3.3	5.0	4.2	0.4	3.1	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IDXX IDEXX Laboratories	2.80	Moderate Buy	$649.44	0.58% Upside
ISRG Intuitive Surgical	2.60	Moderate Buy	$595.95	25.28% Upside
NVST Envista	2.33	Hold	$20.92	-2.75% Downside
ZTS Zoetis	2.50	Moderate Buy	$202.43	29.05% Upside

Current Analyst Ratings Breakdown

Latest IDXX, NVST, ZTS, and ISRG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	ISRG Intuitive Surgical	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/19/2025	ISRG Intuitive Surgical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$615.00
8/15/2025	IDXX IDEXX Laboratories	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$722.00 ➝ $765.00
8/11/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $215.00
8/11/2025	IDXX IDEXX Laboratories	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$510.00 ➝ $700.00
8/5/2025	IDXX IDEXX Laboratories	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$722.00
8/5/2025	IDXX IDEXX Laboratories	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$545.00 ➝ $785.00
8/4/2025	IDXX IDEXX Laboratories	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$640.00
8/4/2025	IDXX IDEXX Laboratories	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$550.00 ➝ $675.00
8/1/2025	NVST Envista	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
8/1/2025	NVST Envista	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$15.00 ➝ $18.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IDXX IDEXX Laboratories	$3.90B	13.25	$12.54 per share	51.48	$18.23 per share	35.42
ISRG Intuitive Surgical	$8.35B	20.42	$7.91 per share	60.14	$50.08 per share	9.50
NVST Envista	$2.51B	1.42	$1.73 per share	12.47	$18.89 per share	1.14
ZTS Zoetis	$9.26B	7.51	$7.08 per share	22.17	$11.23 per share	13.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IDXX IDEXX Laboratories	$887.87M	$12.01	53.72	47.55	4.14	24.41%	64.42%	29.89%	10/30/2025 (Estimated)
ISRG Intuitive Surgical	$2.32B	$7.17	66.30	62.35	5.04	28.51%	14.56%	12.93%	10/16/2025 (Estimated)
NVST Envista	-$1.12B	$0.32	67.31	17.78	1.11	2.11%	4.84%	2.68%	10/29/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.81	27.00	23.24	2.52	27.83%	56.90%	19.54%	11/3/2025 (Estimated)

Latest IDXX, NVST, ZTS, and ISRG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ZTS Zoetis	$1.62	$1.76	+$0.14	$1.61	$2.41 billion	$2.46 billion
8/4/2025	Q2 2025	IDXX IDEXX Laboratories	$3.28	$3.63	+$0.35	$3.63	$1.06 billion	$1.11 billion
7/31/2025	Q2 2025	NVST Envista	$0.24	$0.26	+$0.02	$0.16	$638.21 million	$682.10 million
7/22/2025	Q2 2025	ISRG Intuitive Surgical	$1.93	$2.19	+$0.26	$1.81	$2.35 billion	$2.44 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
ISRG Intuitive Surgical	N/A	N/A	N/A	N/A	N/A
NVST Envista	N/A	N/A	N/A	N/A	N/A
ZTS Zoetis	$2.00	1.27%	N/A	34.42%	14 Years

Latest IDXX, NVST, ZTS, and ISRG Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IDXX IDEXX Laboratories	0.31	1.11	0.79
ISRG Intuitive Surgical	N/A	5.17	4.18
NVST Envista	0.46	2.44	2.08
ZTS Zoetis	1.05	1.76	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IDXX IDEXX Laboratories	87.84%
ISRG Intuitive Surgical	83.64%
NVST Envista	N/A
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
IDXX IDEXX Laboratories	0.98%
ISRG Intuitive Surgical	0.70%
NVST Envista	0.66%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IDXX IDEXX Laboratories	11,000	80.00 million	79.22 million	Optionable
ISRG Intuitive Surgical	15,638	358.48 million	355.97 million	Optionable
NVST Envista	12,300	166.18 million	165.09 million	Optionable
ZTS Zoetis	13,800	443.18 million	442.39 million	Optionable

IDXX, NVST, ZTS, and ISRG Headlines

Recent News About These Companies

Zoetis Inc. $ZTS Shares Purchased by Capital Analysts LLC

August 22 at 6:29 AM | marketbeat.com

Erste Asset Management GmbH Has $17.06 Million Stock Position in Zoetis Inc. $ZTS

August 22 at 6:28 AM | marketbeat.com

Hsbc Holdings PLC Sells 16,056 Shares of Zoetis Inc. $ZTS

August 22 at 5:20 AM | marketbeat.com

Bowen Hanes & Co. Inc. Has $5 Million Stake in Zoetis Inc. $ZTS

August 21 at 7:07 AM | marketbeat.com

Credit Agricole S A Cuts Stock Position in Zoetis Inc. $ZTS

August 21 at 6:51 AM | marketbeat.com

Van Lanschot Kempen Investment Management N.V. Cuts Position in Zoetis Inc. $ZTS

August 21 at 6:37 AM | marketbeat.com

BI Asset Management Fondsmaeglerselskab A S Lowers Stock Position in Zoetis Inc. $ZTS

August 21 at 6:15 AM | marketbeat.com

Andina Capital Management LLC Purchases New Stake in Zoetis Inc. $ZTS

August 21 at 6:05 AM | marketbeat.com

Texas Capital Bank Wealth Management Services Inc Has $8.53 Million Stock Holdings in Zoetis Inc. $ZTS

August 21 at 5:55 AM | marketbeat.com

Bank OZK Raises Stake in Zoetis Inc. $ZTS

August 21 at 5:45 AM | marketbeat.com

1,821 Shares in Zoetis Inc. $ZTS Acquired by Financial Advisors Network Inc.

August 21 at 5:36 AM | marketbeat.com

Wellington Management Group LLP Sells 893,168 Shares of Zoetis Inc. $ZTS

August 21 at 5:27 AM | marketbeat.com

Korea Investment CORP Reduces Stock Position in Zoetis Inc. $ZTS

August 21 at 5:21 AM | marketbeat.com

Northern Trust Corp Has $1.07 Billion Stock Holdings in Zoetis Inc. $ZTS

August 21 at 5:11 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Sold by Cresset Asset Management LLC

August 21 at 4:35 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Acquired by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

August 20 at 9:12 AM | marketbeat.com

Quantbot Technologies LP Purchases 37,334 Shares of Zoetis Inc. $ZTS

August 20 at 8:24 AM | marketbeat.com

Qtron Investments LLC Buys 3,375 Shares of Zoetis Inc. $ZTS

August 20 at 7:56 AM | marketbeat.com

Northwest & Ethical Investments L.P. Lowers Stock Holdings in Zoetis Inc. $ZTS

August 20 at 6:32 AM | marketbeat.com

Raymond James Financial Inc. Boosts Stock Holdings in Zoetis Inc. $ZTS

August 20 at 6:06 AM | marketbeat.com

Zoetis Inc. (ZTS) Announces Issuance of Senior Notes Totaling $1.85 Billion

August 18, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDXX, NVST, ZTS, and ISRG Company Descriptions

IDEXX Laboratories NASDAQ:IDXX

$645.67 +12.63 (+1.99%)

As of 01:42 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Intuitive Surgical NASDAQ:ISRG

$475.71 +5.83 (+1.24%)

As of 01:42 PM Eastern

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Envista NYSE:NVST

$21.53 +1.07 (+5.23%)

As of 01:41 PM Eastern

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Zoetis NYSE:ZTS

$156.86 +1.25 (+0.81%)

As of 01:42 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time